Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
02:26 ET | 1263 | 4.72 |
02:27 ET | 1196 | 4.72 |
02:29 ET | 1425 | 4.72 |
02:31 ET | 27071 | 4.705 |
02:33 ET | 3622 | 4.7 |
02:36 ET | 4000 | 4.7 |
02:38 ET | 3000 | 4.7 |
02:40 ET | 3180 | 4.705 |
02:42 ET | 21731 | 4.695 |
02:44 ET | 4352 | 4.695 |
02:45 ET | 7359 | 4.695 |
02:47 ET | 1137 | 4.695 |
02:49 ET | 3330 | 4.695 |
02:51 ET | 106337 | 4.695 |
02:54 ET | 1300 | 4.695 |
02:56 ET | 2900 | 4.695 |
02:58 ET | 3258 | 4.695 |
03:00 ET | 1300 | 4.695 |
03:02 ET | 47580 | 4.705 |
03:03 ET | 31480 | 4.705 |
03:05 ET | 20910 | 4.7012 |
03:07 ET | 30053 | 4.695 |
03:09 ET | 82826 | 4.695 |
03:12 ET | 28005 | 4.68 |
03:14 ET | 100003 | 4.65 |
03:16 ET | 8758 | 4.655 |
03:18 ET | 40021 | 4.65 |
03:20 ET | 81358 | 4.65 |
03:21 ET | 40827 | 4.63 |
03:23 ET | 4100 | 4.635 |
03:25 ET | 23147 | 4.63 |
03:27 ET | 7501 | 4.63 |
03:30 ET | 25379 | 4.63 |
03:32 ET | 6061 | 4.635 |
03:34 ET | 39529 | 4.62 |
03:36 ET | 15545 | 4.625 |
03:38 ET | 37867 | 4.61 |
03:39 ET | 14007 | 4.615 |
03:41 ET | 6858 | 4.615 |
03:43 ET | 87214 | 4.6 |
03:45 ET | 10289 | 4.6 |
03:48 ET | 24143 | 4.605 |
03:50 ET | 10297 | 4.605 |
03:52 ET | 55637 | 4.595 |
03:54 ET | 221243 | 4.605 |
03:56 ET | 89958 | 4.615 |
03:57 ET | 32906 | 4.615 |
03:59 ET | 198463 | 4.6 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.8B | -13.3x | --- |
Morphic Holding Inc | 2.8B | -16.2x | --- |
Apogee Therapeutics Inc | 2.9B | -23.2x | --- |
SpringWorks Therapeutics Inc | 2.9B | -7.3x | --- |
MoonLake Immunotherapeutics | 3.0B | -59.6x | --- |
CG Oncology Inc | 2.5B | -31.3x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.8B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.48 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -13.3x |
Price/Sales (TTM) | 5,429.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.